News

Novian Reports Solid Financial Performance Amid Market Challenges

Novian Reports Solid Financial Performance Amid Market Challenges

Novian Posts Solid Revenue and Stronger Profitability Despite Headwinds

Novian, the software and IT infrastructure services group, recorded aggregated revenue of EUR 16.4 million in the first half of the year. That’s an 11.1% dip from the same period a year ago, yet the story doesn’t end there. Profitability moved in the right direction: EBITDA came in at EUR 1.1 million, up sharply from EUR 0.2 million a year earlier. In plain terms, tighter cost control and smoother operations helped the group earn more from every euro of revenue.

Operating Result Turns Positive

The improvement showed up in operating profit as well. Novian posted an operating profit of EUR 0.6 million for the first half, a clear turnaround from the EUR 0.3 million operating loss in the first half of 2023. This swing points to strategy taking hold—fewer inefficiencies, better execution, steadier delivery across projects. It’s not just a blip; it reads like the early chapters of a disciplined course correction.

Where the Revenue Came From

Roughly 77% of revenue—EUR 12.6 million—was earned in Lithuania. That home-base strength matters. At the same time, the group continued to work across borders, carrying out projects in 36 countries. The mix suggests a stable core market with growing reach abroad.

Innovation That Keeps Clients Engaged

As CEO Tomas Vitkus put it, the half-year results reflect steady groundwork for growth. He underscored confidence in the group’s specialists and their ability to meet client expectations with fresh solutions and practical consulting. New contracts and recent tender wins back that up, hinting at a healthier pipeline and, by extension, a supportive outlook for both revenue and profit in the periods ahead.

Strategic Projects Spanning Key Sectors

Within software, the group is active in healthcare, tax, and account management projects. One highlight: progress on an e-prescription initiative designed to enable cross-border transactions of prescription medicines within the European Union. It’s the kind of system work that, once running, can make everyday tasks simpler for people and providers alike.

Defence Work and Emerging Technologies

On the defence side, Novian is engaged in projects that call for thoughtful, sometimes novel, uses of technology. Another notable effort is an AI-based X-ray image analysis system intended to help Lithuanian customs operate more efficiently. The common thread is purposeful application—using tools that fit the job and improve throughput.

Consulting That Opens New Doors

Novian Technologies stood out in consulting, particularly in cloud architecture. CEO Gytis Umantas highlighted recent tender wins with public sector organisations as a proof point of the team’s know-how. The message is straightforward: when clients need modern cloud foundations, the company can step in and build what’s required.

Modern IT Infrastructure at Scale

Recent contracts will see Novian Technologies supplying more than 14,500 laptops to over 600 schools across Lithuania. It’s a broad rollout—wide enough to matter in classrooms. Looking ahead, the organisation plans to expand its managed services with tailored packages so clients can pick support levels that fit their needs without overbuying.

High-Performance Computing With Purpose

In high-performance computing (HPC), Novian Technologies is delivering solutions for weather forecasting and climate change modelling. These are complemented by systems that can issue early warnings—tools built not just to compute, but to inform decisions when time is tight.

Digitisation and Media Work That Preserves Access

The group is also continuing long-running efforts in archive and media digitisation. One flagship project is the digitisation of Estonia’s Soviet-era cultural archive, with the goal of making 2 million historical files accessible online. In parallel, the group is setting up a digitalisation center in Sint Maarten aimed at streamlining public services. Different places, different needs, one throughline: turning paper and tape into searchable, usable records.

About the Novian Group

Novian brings together companies including Novian Technologies, Novian Systems, and Novian Pro, with subsidiaries in Estonia, Moldova, Norway, and Rwanda. The group is backed by INVL Technology, an investor focused on IT-related businesses. Structure matters here—a mix of software, infrastructure, and services gives Novian room to build systems end to end.

For more information, please contact:
Kazimieras Tonk?nas
Managing Partner, INVL Technology
e-mail k.tonkunas@invltechnology.lt

Frequently Asked Questions

What did Novian report for the first half of 2024?

Revenue was EUR 16.4 million. Profitability improved: EBITDA reached EUR 1.1 million and operating profit was EUR 0.6 million, compared with an operating loss in the first half of 2023.

How did profit rise even though revenue fell?

The group tightened costs and improved day-to-day execution. Those operational efficiencies lifted EBITDA from EUR 0.2 million to EUR 1.1 million and turned the operating result from a loss to a profit.

Where does most of Novian’s revenue come from?

About 77%—EUR 12.6 million—was generated in Lithuania. Beyond that, the group is active in 36 countries, combining a strong home market with international delivery.

Which projects are shaping Novian’s pipeline right now?

Key efforts include healthcare, tax, and account management systems; the EU-focused e-prescription initiative for cross-border medicine transactions; defence-related technology projects; an AI-based X-ray image analysis system for Lithuanian customs; large-scale laptop supply for schools; HPC solutions for weather and climate modelling; and archive digitisation, including Estonia’s Soviet-era cultural materials.

Who can I contact for more details?

Reach out to Kazimieras Tonk?nas, Managing Partner at INVL Technology. The email address is listed above in the contact section.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

CaliberMRI Revolutionizes Preclinical MRI with New Phantom

Updated Category News Views 107

CaliberMRI: Pioneers Shaping the Future of MRI Hot off the press, folks—CaliberMRI, known for setting the bar high in MRI standardization, has unleashed a new beast on the scene. Enter Model 340, a preclinical quantitative MRI phantom, ready to knock the socks off high-field systems. They’re talking 4.7T, 7T, and a jaw-dropping 9.4T compatibility here. This isn't just...

Continue Reading
LINE-X Seeks Veterans to Propel Franchise Growth

Updated Category News Views 55

If you've ever wondered about the intersection of military discipline and entrepreneurial spirit, LINE-X is handing veterans the keys, quite literally. With a nod to leathernecks and GIs, they're slashing their franchise fee by 25% for U.S. veterans aiming to trade sergeants' stripes for business clout. Franchising for Veterans: A Tailored Offer So, the word on the street...

Continue Reading
Peanuts and Diabetes: A Surprising Health Link

Updated Category News Views 68

A Nutty Approach to Diabetes Prevention Who would've thought peanuts could pack such a punch against diabetes? Amid the usual suspects of healthy foods, it's these humble legumes that are making headlines. The Peanut Institute, backed by fresh research, is shining a spotlight on their potential role in preventing type 2 diabetes, a disease that's affecting roughly 40...

Continue Reading
Untapped $41B VA Loan Potential: Opportunities Missed

Updated Category News Views 106

VA Loans: Unused Potential Sits at $41 Billion Are you telling me we're leaving $41 billion just sitting on the table in the form of untapped VA loans? That's the figure staring us in the face according to Veterans United's latest analysis. It's not just about numbers; it's a head-scratcher given the growing VA loan market share, which hit 10% last year. Where's the...

Continue Reading
Key Insights Await in Sectra's Six-Month Report

Updated Category News Views 75

Sometimes the anticipation of a financial report presentation feels akin to waiting for a storm to pass or the sun to finally break through after what seems like endless rain. That’s the kind of vibe we're getting from Sectra's upcoming six-month report presentation. Slated for November 25, President Torbjörn Kronander and CFO Jessica Holmquist will be stepping up to...

Continue Reading
AI Shakes Up Boat Discovery: Traffic Soars for Leaders

Updated Category News Views 28

AI's Surge in the Boating World Well, look who’s riding the AI wave—it's our old friends at Boat Trader and YachtWorld, leaving the competition coughing in their slipstream. Similarweb data throws some cold, hard fish onto the deck, showing these two raking in over 17 times the AI-referred traffic compared to their closest peers. If you’re sniffing around for where...

Continue Reading
Accro's Vitiligo Trial Moves Fast with Fosun's Boost

Updated Category News Views 112

Launching into Vitiligo Treatment Trials I'll tell you, the biotech world isn't for the faint-hearted, especially when you're juggling hefty terms like 'TYK2/JAK1'. But here we are, watching Accro Bioscience and Fosun Pharma dive headlong into the vitiligo space with this Phase II/III trial of AC-201. They've bagged the IND clearance, and now the first patient is in the...

Continue Reading
CPC Biotech Debuts Quattroflow HTX Pump Drive

Updated Category News Views 51

Innovative Moves in Bioprocessing Let's get one thing clear right off the bat—CPC Biotech, part of Dover (NYSE: DOV), just sent a signal loud and clear with their new Quattroflow HTX all-in-one pump drive. With a slick touchscreen, flexible control options, and self-touting accuracy, this thing sounds like it's set to change the game for biopharmaceutical processing....

Continue Reading
AI Adoption Institute Targets ROI with Peer Circles

Updated Category News Views 73

Transforming AI from Cost to Profit Alright folks, we all know AI's the flashy tool everyone's jumping on like it's the latest tech bandwagon. But here’s the raw deal: most of these shiny AI investments ain't paying back a damn thing. Enter the AI Adoption Institute (AiAi)—a new player in Denver aiming to salvage this mess and make AI about actual returns. Peering...

Continue Reading
Bramshill Fund Takes Top Spot in 2026 Fund Awards

Updated Category News Views 78

Another Feather in Bramshill's Cap They've done it again, folks. The Bramshill Multi-Strategy Income Fund has just snagged the 40 Act Fund of the Year award at the 2026 Hedge Fund Performance Awards. This ain't just another plaque for the wall; it's a nod to some serious heavy lifting by the folks handling this beast of a portfolio. The award, dished out by With...

Continue Reading

Top 5 Most Recently Viewed Articles

Twilio's Q4 Results Spark Diverse Analyst Reactions

Updated Category News Views 232

Twilio Inc Fourth Quarter Overview Twilio Inc reported notable financial results for the fourth quarter, capturing the attention of several analysts within the market. The company’s performance has sparked diverse reactions, particularly regarding its future guidance and the evolving role of artificial intelligence within its operations. Market Response to Q4 Earnings...

Continue Reading
FHLBank Indianapolis Dividends for Second Quarter of 2025

Updated Category News Views 180

FHLBank Indianapolis Declares Second Quarter Dividends FHLBank Indianapolis recently announced its second quarter dividends for 2025, detailing robust financial strategies and growth, as reflected in the declared dividends on Class B-2 activity-based capital stock and Class B-1 non-activity-based stock. These dividends have been set at annualized rates of 9.50% and 4.50%,...

Continue Reading
Neurogen Biomarking Partners with Quanterix for Alzheimer's Testing

Updated Category News Views 255

Revolutionizing Alzheimer's Detection with Neurogen Biomarking Neurogen Biomarking is making significant strides in the healthcare landscape by introducing a pioneering blood test aimed at the early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). This innovative approach leverages advanced biomarker technology developed by Quanterix Corporation,...

Continue Reading
Kepler Robotics Launches Innovative Humanoid Robot for Industries

Updated Category News Views 296

Revolutionizing Industries with the K2 Bumblebee Shanghai Kepler Robotics Co., Ltd has excitedly announced the commencement of mass production of its K2 "Bumblebee" model, confirming that the world's first commercially available hybrid-architecture humanoid robot is now shipping to eager customers. Milestone in Humanoid Robotics This significant development not only marks...

Continue Reading
Syntara Limited Reveals Groundbreaking Data in Myelofibrosis Trials

Updated Category News Views 259

Positive Interim Data from Syntara's Clinical Trials Syntara Limited, known for its innovative approach in drug development, has unveiled promising interim data concerning its ongoing Phase 2 study of SNT-5505. This clinical trial focuses on myelofibrosis, a complex bone marrow disorder that often leads to severe health complications. Details of the Clinical Trial The...

Continue Reading